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BACKGROUND/AIMS: Biological and epidemiological data suggest that vitamin D levels may influence cancer
development. Several single nucleotide polymorphisms have been described in the vitamin D receptor (VDR) gene in
associationwith cancer risk.We aimed to investigate the association of VDR gene polymorphismswith hepatocellular
carcinoma (HCC) development in chronic hepatitis C patients.METHODS: In a cross-sectional, hospital-based setting,
340 patients (201 chronic hepatitis, 47 cirrhosis and 92 HCC) and 100 healthy controls receiving VDR genotyping
(bat-haplotype: BsmI rs1544410 C, ApaI rs7975232 C and TaqI rs731236 A) were enrolled. RESULTS: Patients with
HCC had a higher frequency of ApaI CC genotype (P= 0.027) and bAt[CCA]-haplotype (P= 0.037) as compared to
control subjects. Therewere no differences in BsmI and TaqI polymorphisms between two groups. In patientswith
chronic hepatitis C, HCC subjects had a higher frequency of ApaI CC genotype and bAt[CCA]-haplotype than those
with chronic hepatitis (P = 0.001 and 0.002, respectively) and cirrhosis (P = 0.019 and 0.026, respectively). After
adjusting age and sex, logistic regression analysis showed that ApaI CC genotype (odds ratio: 3.02, 95% confident
interval: 1.65-5.51) was independently associated with HCC development. CONCLUSION: VDR ApaI polymorphism
plays a role in the development of HCC among chronic hepatitis C patients. Further explorations of this finding and its
implications are required.
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Hepatitis C virus (HCV) infection is one of the major public health
problems worldwide [1]. Chronic HCV infection is characterized by a
high rate of progression to fibrosis, chronic hepatitis, leading to cirrhosis
and ultimately to hepatocellular carcinoma (HCC) [2–4]. Although the
relationship between HCV and the development of HCC is well
established, the pathogenetic mechanism of hepatocarcinogenesis,
including host- and viral-related factors, is still unknown. It is prudent
to affirm that differences in the incidence rates and the strong gender
distribution in HCC are not entirely due to differences in the exposure
to the causative agents [5,6]. Of great importance, genetic factors can
also contribute, particularly gene polymorphisms of inflammatory
cytokines and growth factor ligands and receptors [7].
Vitamin D is involved in the metabolism of skeleton as a systemic
hormone but also has important roles in the regulation of host
immune responses, fibrogenesis and development of cancer through
vitamin D receptor (VDR) [8–14]. Previous data have suggested that
vitamin D levels may influence cancer development. In particular,
several single nucleotide polymorphisms have been described in theVDR gene, and some polymorphisms are associated with tumor
occurrence [12–16]. For instance, VDR polymorphisms have been
related to cancers of the breast, prostate, skin, colon-rectum, bladder
and kidney, although with conflicting observations [12–16]. VDR
polymorphisms have also been investigated in the context of some
chronic liver diseases, such as chronic hepatitis B, primary biliary
cirrhosis and autoimmune hepatitis [17–19]. In a recent published
study, VDR polymorphism may be used as a molecular marker to
predict the risk and to evaluate the disease severity of HCC in patients
with chronic hepatitis B [20].
Table 1. Baseline Characteristics of the Studied Population
Con (n = 100) CH (n = 201) LC (n = 47) HCC (n = 92) P-value
Age (years) 52.7 ± 15.6c 52.4 ± 11.5e 55.9 ± 10.0f 64.5 ± 11.6cef b0.001
Male gender (%) 43 (43%)c 101 (50%)e 21 (45%)f 64 (70%)cef 0.001
BMI (kg/m2) − 24.6 ± 3.6 25.3 ± 3.6 24.2 ± 3.6 0.239
AST (U/L) 42 ± 33abc 77 ± 58ade 107 ± 41bd 102 ± 80ce b0.001
ALT (U/L) 50 ± 53abc 138 ± 131ae 147 ± 76bf 94 ± 76cef b0.001
Platelet (104/μL) − 18.7 ± 5.4ab 13.7 ± 6.1a 13.2 ± 7.1b b0.001
Data are expressed as mean ± standard deviation or number (percentage).
P-value by one-way ANOVA test or x2 test; a Significant differences between Con and CH; b Significant
differences between Con and LC; c Significant differences between Con and HCC; d Significant differences
between CH and LC; e Significant differences CH and HCC; f Significant differences between LC and HCC
with LSD post-hoc correction or x2 test.
Abbreviation: Con: healthy control; CH: chronic hepatitis; LC: liver cirrhosis; HCC: hepatocellular
carcinoma; BMI: body mass index; AST: aspartate aminotransferase; ALT: alanine aminotransferase.
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between VDR polymorphisms and the occurrence of HCC. In this
present study, we investigated the role of VDR gene polymorphisms
in the susceptibility and clinicopathological status of HCC in Chinese
subjects with chronic HCV infection.
Patients and Methods
Patients
From August 2011 to July 2013, a total of 340 patients with
chronic HCV infection receiving long-term follow up in a single
center were enrolled. They included 201 chronic hepatitis, 47
cirrhosis and 92 HCC patients. All patients were seropositive for
HCV antibody (by third-generation enzyme-linked immunosorbent
array (ELISA) and HCV RNA (Amplicor™, Roche Diagnostics,
Branchburg, NJ, USA). Patients were excluded if they were positive
for serum hepatitis B surface antigen or anti-human immunodefi-
ciency virus antibody, or exhibited other causes of hepatocellular
injury (e.g. any history of alcoholism, autoimmune hepatitis, primary
biliary cirrhosis and severe nonalcoholic liver disease with metabolic
syndrome). During the same period, 100 healthy volunteers were
collected as controls.
Pathologic diagnoses of chronic hepatitis or cirrhosis were made
by percutaneous liver biopsies according to the modified Knodell
histologic activity index [21], which were analyzed by pathologists
who were blind to the patients’ characteristics. Diagnosis of HCC
was based on either the histopathologic findings in tumor tissues
or typical HCC features of dynamic images if the nodules were
larger than 1 cm in cirrhotic livers [22]. This study protocol
conformed to the ethical guidelines of the 1975 Declaration of
Helsinki and was approved by the ethical committees of Chang
Gung Memorial Hospital. All patients gave written informed
consent before enrollment.
Detection of VDR Polymorphisms
The DNA was extracted from peripheral blood leukocytes using the
Qiagen DNA isolation kit (Qiagen, Germany). The VDR genotype was
determined by polymerase chain reaction (PCR) amplication and
restriction length fragment polymorphisms (RFLP) as previously
described [23]. For the detection of BsmI polymorphisms, a forward
primer in exon 7 (5’-CAACCAAGACTCAAGTACCGCGT
CAGTGA-3’) and a reverse primer in intron 8 (5’-AACCAGCGGAA
GAGGTCAAGGG) was used. For the detection of ApaI and TaqI
polymorphisms, a forward primer in exon 8 (5’-CAGAGCATGGA
CAGGGAGCAA) and a reverse primer in exon 9 (5’-GCAACTCCT
CATGGCTGAGGTCTC) was used. The PCR products for BsmI
polymorphisms were 820 base pair (bp), and for ApaI/TaqI polymor-
phisms they were 745 bp. The PCR mix contained 5 μL of each primer
(10 pmol), 5 μL buffer, 1.5 μL MgCl2 (50 mM), 5 μL template DNA
(50–100 ng), 5 μL dNTPs (2 mmol/L), Taq polymerase (MBI) 2 μL,
H2O 26.5 μL. The DNA template was denatured at 95°C for 2 min. A
total of 40 cycles of PCR were performed, consisting of a denaturation
step for 45 sec at 94°C, an annealing step for 45 sec at optimum
temperature (67°C for Apa I/Taq I and 60°C for Bsm I), and an extension
reaction for 1 min at 72°C. A final extension step at 72°C for 2 min was
added after the last PCR cycle.
After amplication, the PCR products were digested with BsmI,
ApaI and TaqI endonucleases. Following restriction endonuclease
digestion, genotyping was determined by ethidum bromide-UVBillumination of the fragments separated on gels of 2% agarose. The
presence of BsmI, ApaI or TaqI restriction site was defined as the
lower-case ‘b’, ‘a’ and ‘t’, respectively, and the absence of the site was
defined as the upper-case ‘B’, ‘A’ or ‘T’. The BsmI restriction site
resulted in two fragments (645 bp and 177 bp). Digestion with ApaI
produced two fragments of 531 bp and 214 bp when the restriction
site was present. Digestion with TaqI resulted in three fragments of
approximately 205, 290 bp and 245 bp in the presence of TaqI
polymorphic site, and in fragments of 245 and 495 bp in the absence
of a TaqI polymorphic site.
Statistical Analysis
Continuous data are expressed as mean ± standard deviation, and the
categorical data are expressed as number (percentage). Comparisons of
differences in the categorical date between groups were performed using
the chi-square test. Distributions of continuous variables were analyzed
by the Student’s t-test or one-way ANOVA test with least significant
difference (LSD) post-hoc correction between groups where appropriate.
Stepwise logistic regression analysis was performed to assess the influence
of each factor on the risk of developing HCC. All analyses were
carried out using SPSS software version 15.0 (SPSS Inc., Chicago, IL).
All tests were 2-tailed, and a p-value of less than 0.05 was considered
statistically significant.
Results
Baseline Features of the Studied Population
The basic demographical and clinical features of the patients are shown
in Table 1. The mean age of HCC patients was significantly higher than
those with cirrhosis, chronic hepatitis and controls (P b 0.001). Patients
with HCC had a higher male-to-female ratio than other groups (P =
0.001). There was no significant difference in BMI among these groups.
The HCC subjects had lower platelet count compared to those with
chronic hepatitis; whereas the platelet count was comparable between
cirrhosis and HCC groups.
The Distribution of Frequencies of VDR Genotype
and Haplotype
Firstly, HCC patients were compared with a control cohort of 100
healthy volunteers with regard to allelic frequency. The distribution
of the alleles of BsmI, ApaI and TaqI was in accordance with the
Hardy-Weinberg equilibrium in both individuals of HCC and controls
(P N 0.05 for any). Patients with HCC had a higher frequency of ApaI
CC genotype (P = 0.027) and bAt[CCA]-haplotype consisting of BsmI
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Figure 1. Association of VDR gene polymorphisms with the
disease severity in chronic HCV infection. Bsm I (P = 0.343),
Apa I (P = 0.024) and Taq I (P = 0.195).
Table 2. The Distribution of Frequencies of VDR Genotype and Haplotype Among Controls and
Different Clinical Stages of Chronic HCV Infection
Con (n = 100) CH (n = 201) LC (n = 47) HCC (n = 92)
BsmI (rs1544410)
TT 0 (0%) 0 (0%) 0 (0%) 0 (%)
TC 11 (11%) 13 (6%) 6 (13%) 7 (8%)
CC 89 (89%) 188 (94%) 41 (87%) 85 (92%)
T vs. C allele 11:189 13:389 6:88 7:177
ApaI (rs7975232)
CC 55 (55%) a 102 (51%)b 24 (51%)c 65 (71%)abc
CA 40 (40%)d 82 (41%)e 19 (40%) 24 (26%)de
AA 5 (5%) 17 (8%) 4 (9%) 3 (3%)
C vs. A allele 150:50f 286:116g 67:27h 154:30fgh
TaqI (rs731236)
GG 0 (0%) 0 (0%) 0 (0%) 0 (0%)
AG 14 (14%) 15 (7%) 7 (15%) 6 (7%)
AA 86 (86%) 186 (93%) 40 (85%) 86 (93%)
G vs. A allele 14:186 15:387 7:87 6:178
BsmI–ApaI–TaqI
TAG (BaT) 10 (10%) 12 (6%) 5 (11%) 5 (5%)
CCA (bAt) 54 (54%)i 102 (51%)j 24 (51%)k 64 (70%)ijk
CAA (bat) 31 (31%) 83 (41%)l 15 (32%) 21 (23%)l
CAG (baT) 4 (4%) 3 (1%) 2 (4%) 0 (0%)
TAA (Bat) 0 (0%) 1 (1%) 1 (2%) 1 (1%)
TCG (BAT) 0 (0%) 0 (0%) 0 (0%) 1 (1%)
TCA (BAt) 1 (1%) 0 (0%) 0 (0%) 0 (0%)
CCA vs. TAG & CAA 54:41m 102:95n 24:20 64:26mn
Data are expressed as number (percentage). P-value by x2 test or Fisher’s exact test;
Abbreviation: VDR, vitamin D receptor; Con: healthy control; CH: chronic hepatitis; LC: liver cirrhosis;
HCC: hepatocellular carcinoma.
a P = 0.027; bP = 0.001; cP = 0.026; dP = 0.047; eP = 0.018; fP = 0.044; gP = 0.001; hP = 0.019; iP = 0.037;
jP = 0.003; kP = 0.041; lP = 0.002; mP = 0.048; nP = 0.002
Table 3. Univariate Analyses and Stepwise Multivariate Analyses of Factors Associated with the
Risk of HCC in Patients with Chronic HCV Infection
Univariate Analyses Stepwise Multivariate Analyses
Odds Ratio (95% CI) P-value Odds Ratio (95% CI) P-value
Age (per 1 year increase) 1.10 (1.07-1.13) b0.001 1.10 (1.07-1.14) b0.001
Male gender 2.36 (1.42-3.93) 0.001 3.90 (2.07-7.35) b0.001
BMI 0.96 (0.89-1.03) 0.212
Platelet (b15 × 104/μL) 4.36 (2.59-7.34) b0.001 4.20 (2.26-7.83) b0.001
CCA vs. TAG&CAA 2.25 (1.33-3.78) 0.002 − −
BsmI CC type 1.01 (0.41-2.48) 0.987 − −
ApaI CC type 2.33 (1.40-3.89) 0.001 2.77 (1.47-5.21) 0.002
TaqI AA type 1.40 (0.55-3.56) 0.486 − −
Abbreviations: HCC: hepatocellular carcinoma; HCV, hepatitis C virus; CI, confidence interval;
BMI: body mass index.
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subjects. For the BsmI and TaqI polymorphisms, no significant
associations were found.
Figure 1 shows the association of VDR gene polymorphisms with
the disease severity in chronic HCV infection. Patients carrying the
corresponding ApaI CC genotype had a higher prevalence (34%) of
HCC than those with CA (19.2%) or AA type (12.5%) (P = 0.024).
In contrast, BsmI and TaqI polymorphisms were not significantly
associated with disease severity of chronic HCV infection. As shown
in Table 2, patients with HCC carried a higher ratio of ApaI CC
genotype compared to those with chronic hepatitis (P = 0.001) or
cirrhosis (P = 0.026).
Factors Associated with Developing HCC by Logistic
Regression Analysis
As shown in Table 3, univariate analysis revealed that age, male
gender, lower platelet count (b15 × 104/μL), the carriage of bAt[CCA]-
haplotype and ApaI CC genotype were factors significantly associated
with developing HCC. Stepwise logistic regression analysis showed that
age (odds ratio (OR): 1.10, 95% confidence interval (CI): 1.07-1.14,
P b 0.001), male gender (OR: 3.90, 95% CI: 2.07-7.35, P b 0.001),
low platelet count (b15 × 104/μL)(OR: 4.20, 95% CI: 2.26-7.83,P b 0.001) and the carriage of ApaI CC genotype (OR: 2.77, 95%
CI: 1.47-5.21, P = 0.002) were the independent predictors.
Comparison Between Chronic HCV Patients with Apa I CC
Type and CA/AA Type
Since ApaI CC genotype was a significant factor associated with
developing HCC, we thus compared the chronic hepatitis C patients
with ApaI CC type and CA/AA type. As shown in Table 4, patients
carrying ApaI CC genotype had a higher prevalence of HCC and pre-
existing cirrhosis and a higher ratio of BsmI CC type and TaqI AA
type as compared to those with ApaI CA/AA type.
Discussion
Hepatocarcinogenesis is a complex and multi-factorial process, in
which both environmental and genetic features interfere and
contribute to malignant transformation [24]. The identification of
genetic factors related to HCC susceptibility may improve our
understanding of the various biological pathways involved in
Table 4. Comparison Between Chronic HCV Patients with ApaI CC Type and CA/AA Type
ApaI CC (N = 191) ApaI CA/AA type (N = 149) P-value
Age (years) 55.8 ± 12.7 56.6 ± 12.2 0.600
Male gender (%) 106 (55%) 80 (54%) 0.412
BMI (kg/m2) 24.6 ± 3.2 24.6 ± 4.1 0.908
LC* 85 (45%) 50 (34%) 0.026
HCC 65 (34%) 27 (18%) 0.001
AST (U/L) 83 ± 57 96 ± 78 0.139
ALT (U/L) 131 ± 133 123 ± 83 0.522
Platelet (104/μL) 16.1 ± 6.3 17.0 ± 6.8 0.153
BsmI CC type 190 (99%) 124 (83%) b0.001
TaqI AA type 190 (99%) 122 (82%) b0.001
Data are expressed as mean ± standard deviation or number (percentage). P-value by Student’s
t-test or x2 test. *Analysis included 47 LC patients without HCC and 88 HCC patients with
underlying LC.
Abbreviations: HCV: hepatitis C virus; BMI: body mass index; LC: liver cirrhosis; HCC: hepatocellular
carcinoma; AST, aspartate transaminase; ALT, alanine transaminase.
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preventative intervention. Numerous candidate-gene studies have
reported associations between single nucleotide polymorphism and
the development of HCC [24–28]. In this study, we investigated the
possible association between the VDR gene polymorphisms and
HCC in a Chinese population with chronic HCV infection. Our data
showed that patients with HCC had a higher frequency of ApaI CC
genotype and bAt[CCA]-haplotype as compared to control subjects.
Furthermore, stepwise logistic regression analyses revealed that ApaI
CC genotype was an independent factor, suggesting that the ApaI C
polymorphisms may be used as a molecular marker to predict the risk
of HCC in the patients infected with HCV.
Association studies of several polymorphisms in the VDR gene
have been performed to investigate their implication with severity of
chronic liver disease [17–20]. One of the common genetic variations
of VDR gene is the bat-haplotype consisting of BsmI, ApaI and TaqI
[29]. These genetic variations have been described as important
modulators of several chronic liver diseases such as primary biliary
cirrhosis and autoimmune hepatitis [18,19]. Recently, bAt [CCA]-
haplotype VDR polymorphisms have been reported to influence
antiviral response to peginterferon plus ribavirin therapy in chronic
hepatitis C [30,31]. In particular, Baur et al. have demonstrated that
bAt[CCA]-haplotype and ApaI CC genotype are both significantly
associated with a rapid fibrosis progression rate and with the presence
of cirrhosis in patients with chronic hepatitis C [32]. This result was
similar to that in our study showing that patients carrying ApaI CC
genotype had a higher prevalence of cirrhosis compared to those with
ApaI CA/AA type if the HCC patients with pre-existing cirrhosis were
enrolled for analysis. Moreover, our data further showed that ApaI C
polymorphisms might not only affect the fibrosis progression and the
presence of cirrhosis, but also have a direct association with HCC
development in chronic HCV infection.
Two recent studies have reported the relationship between VDR
gene polymorphisms and HCC development in patients with chronic
HCV infection [33,34]. Falleti et al. have demonstrated that VDR
genetic polymorphisms are significantly associated with the occurrence
of HCC in cirrhotic patients who underwent liver transplantation [33].
However, this relationship is more specific for patients with an alcoholic
etiology, but not in those with cirrhosis of viral origin. This discrepancy
could be explained by the limited case numbers in the subgroup analysis
of virus-cirrhotic subjects. The other study has reported that genetic
variations in CYP2R1, GC, and DHCR7 are associated withprogression to HCC in patients with chronic hepatitis C according to
four heterogeneous independent cohorts [34].
In this study, we cannot prove the causal relationships between
genetic variations and distinct clinical phenotypes. However, the
significant association between the polymorphisms in VDR which
serves as the physiological target to mediate vitamin D effects and
HCV-induced HCC suggests that an impaired vitamin Dmetabolism
contributes to hepatocarcinogenesis in chronic HCV infection.
Although serum vitamin D levels and history regarding vitamin D
intake (dietary or supplemental) were not available, this could be
justified since VDR gene variants modulate biological effects of
vitamin D without influencing vitamin D plasma levels [29,35]. In
addition, 25(OH)D3 serum levels strongly fluctuate during seasons,
with age, and as a consequence of numerous other conditions [8,36].
In conclusion, the present study suggests a significant association
of VDR ApaI polymorphism with the development of HCC in
chronic HCV infection. The characterization of VDR genetic
polymorphisms in HCV carriers may help to identify those who are
at high risk of developing HCC. This observation needs to be
validated in further studies.
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